Colgate-Palmolive CL

Reference table

1. The June 2026 quarter, decomposed the way the company decomposes it

All figures filing-verified from the 10-Q filed 2026-07-31.

The entire GAAP-to-adjusted gap in this quarter is one line: $129M of Strategic Growth and Productivity Program charges booked in Corporate, which is why "Other (income) expense, net" went from $26M to $150M. That is a 15% adjustment to earnings per share, on a programme that has now been running for four quarters and has twelve more to go.

Segment detail — net sales and operating profit, filing-verified ($M):

Four observations, and the first is the one that matters most.

North America is shrinking and the company says why. Net sales fell 3.0% to $891M, driven by volume down 3.9% partially offset by price up 0.9%, with foreign exchange flat — so organic sales also fell 3.0%. The 10-Q: "The decrease in organic sales in North America... was primarily due to decreases in Oral Care and Personal Care organic sales. The decrease in Oral Care was primarily due to an organic sales decline in the toothpaste category. The decrease in Personal Care was primarily due to organic sales declines in the bar soap and body wash categories." A 3.9% volume decline in the United States, in toothpaste, is the single most important fact in this file. Against that, North American operating margin rose 120 basis points to 21.6% on funding-the-growth savings — so the segment is defending profit by holding price and cutting cost while losing units, which works until it does not.

Latin America is carrying the company, and 8.4 points of its 13.7% growth was currency. Reported net sales rose 13.7% on volume +2.6%, price +2.8% and foreign exchange +8.4% — organic +5.3%, led by Mexico, Brazil and Argentina. At $1,372M of net sales and $418M of operating profit, Latin America is 25.6% of sales and 41.1% of pre-corporate segment operating profit at a 30.4% margin — by far the highest in the company. A currency reversal in Latin America is the most mechanically dangerous thing that could happen to Colgate's reported numbers.

Europe is buying volume with price. EMEA grew net sales 3.5% on volume +3.2% and net selling prices of MINUS 1.2%. That is one of the two regions where the pricing-power claim in the knowledge base is directly contradicted by the disclosure.

Hill's is growing on price alone. Net sales +3.4% on price +3.9%, foreign exchange +0.6% and volume MINUS 1.2%, with the Prime100 acquisition adding 0.6 points to volume — so underlying volume fell about 1.8%. Organic sales +2.1%, "including a negative impact from lower private label pet food sales (200 bps)". The best business Colgate owns, at a 22.5% segment margin, sold fewer units than a year ago.

2. The restructuring programme that keeps getting bigger

This is the corporate action the payload does not contain, and it is the reason GAAP and adjusted earnings point in opposite directions.

From the 8-K filed 2026-05-01, Item 2.05:

> "As previously disclosed, on July 31, 2025, the Company's Board of Directors approved a three-year productivity program to drive future growth and support the Company's 2030 strategy (the 'Strategic Growth and Productivity Program')... Building on the successful implementation of the Strategic Growth and Productivity Program to date, on April 30, 2026, the Company's Board approved an expansion of the program... The Strategic Growth and Productivity Program is now estimated to result in cumulative pre-tax charges, once all initiatives are approved and implemented, totaling between $350 million and $550 million, increased from $200 million to $300 million."

The composition and timing, all from the same filing:

Allocation by business, as disclosed: North America 5-10%, Latin America 15-20%, Europe, Middle East & Africa 25-30%, Asia Pacific 10-15%, Hill's Pet Nutrition 10-15%, Corporate 20-25%.

Three things follow and each is stated as an observation rather than a criticism.

The programme roughly doubled in size nine months after approval. From a $250M midpoint to a $450M midpoint. A restructuring that is enlarged 80% before its first year is complete is either evidence of an ambitious management team finding more savings, or evidence that the first estimate was wrong. The disclosure supports the first reading and does not exclude the second.

It runs to the end of 2028, so charges will be excluded from adjusted earnings in at least eleven more quarters. This house's standing position is that a cost incurred every quarter for fourteen quarters is a cost of doing business, and the GAAP figures — operating profit MINUS 6%, EPS MINUS 5.5% — are reported here alongside the adjusted ones rather than beneath them.

Europe, Middle East and Africa takes the largest regional share at 25-30%, which is consistent with a region where the company is buying volume with a 1.2% price cut.

And it is not the first. The 10-K refers to the prior "2022 Global Productivity Initiative" whose charges ran through FY2024. Colgate has been running a restructuring programme continuously since 2022.

3. The Filorga write-down and what it says about the growth strategy

In the fourth quarter of 2025 Colgate reported a net LOSS of $37M. The inc_q block contains this and offers no explanation. The 10-K does:

> "In the fourth quarter of 2025, we recorded a non-cash charge of $794 aftertax ($919 pretax) to adjust the carrying values of goodwill and intangible assets related to the skin health business. Given lower than expected category growth rates and weaker than expected performance, particularly in China, we have lowered our outlook for the skin health business, primarily Filorga."

And in more detail:

> "the Company concluded that the carrying value of the Filorga trademark and customer relationships exceeded their estimated fair values and recorded impairment charges of $244 and $93, respectively, reducing their combined carrying values to an immaterial amount as of December 31, 2025. After adjusting the carrying values of the Filorga trademark and customer relationship intangible assets, the Company completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $582 in the skin health reporting unit, reducing the carrying value of goodwill to $51 as of December 31, 2025."

That is a complete write-off of an acquired brand's intangible value — $244M of trademark and $93M of customer relationships taken to "an immaterial amount", plus $582M of goodwill. The consequences run through the FY2025 income statement: GAAP operating profit fell 23% to $3,306M from $4,268M; GAAP diluted EPS fell to $2.63 from $3.51, of which $0.98 was the impairment; and on a non-GAAP basis operating profit was $4,347M against $4,353M — essentially flat.

The reason this matters beyond the accounting: skin health was Colgate's one attempt to buy into a faster-growing adjacent category. It has been written to a $51M goodwill stub. The remaining growth options in this company are Hill's Pet Nutrition, whose volumes are falling, and the Prime100 fresh-pet-food business bought for AU$471M ($301M) on 2025-04-30, which contributed 0.6 percentage points to Hill's volume this quarter. The exponential score of 2 is a direct consequence of those two sentences.

4. Balance sheet, cash flow and a book value that cannot be used

Filing-verified at 2026-06-30 ($M):

Colgate's shareholders' equity is $236 million against $16,790 million of total assets, and this is not distress — it is the arithmetic outcome of $28,931 million of treasury stock repurchased over decades against $27,085 million of retained earnings. Every equity-based ratio in the payload is therefore correct and useless: priceToBookRatioTTM 312.3x, debtToEquityRatioTTM 33.3x, returnOnEquityTTM 631%, bookValuePerShareTTM $0.711, tangibleBookValuePerShareTTM MINUS $5.058. All are rejected as lenses for this name and none appears anywhere else in this dive. The measures that do work are return on invested capital (29.9%), return on capital employed (40.8%) and free-cash-flow conversion.

Debt is modest and the maturity profile has improved. Debt payable within one year fell from $1,117M to $34M in six months as Colgate termed out into long-term debt, which rose from $6,871M to $7,823M. Net debt of $6,487M against roughly $5.0bn of trailing adjusted EBITDA is about 1.3x — comfortable, and the company has four series of notes listed on the NYSE maturing 2029 through 2039.

Cash flow, and the vendor's figures here are exactly right.

All six of those cash-flow figures match the 10-K to the dollar. capexToDepreciationTTM of 0.931 against $630M of depreciation is entirely plausible. Capex is verified clean and guided higher: the 10-K states capital expenditures for 2026 are expected to be "approximately 3.0% of Net sales", which on consensus revenue of $21.42bn is roughly $643M, up 14% on FY2025's $564M.

Capital return covers 83% of free cash flow. Dividends of $1,823M are a 2.27% yield on dividendPerShareTTM of $2.10; buyback of $1,210M is 1.63% of market capitalisation. Total shareholder yield approximately 3.9%. Note the buyback fell 30% in FY2025 as the impairment year absorbed cash.

5. Valuation — priced in or room?

At $92.54 (market cap $74.05B, 797,172,829 shares per the 10-Q):

Estimate coverage is oddly lopsided and the FY2026 EPS row is thin. 15 analysts on FY2026 revenue but only 7 on FY2026 EPS, rising to 12 on FY2027 and falling to 5 on FY2028 and 1 on FY2029 and FY2030. The FY2029 and FY2030 rows rest on a single analyst and are excluded from every conclusion. The FY2027 EPS range is $3.960 to $4.250, a 7.3% spread — the narrowest in this batch, which is what a staple with a four-decade operating history produces.

est.ebitdaAvg and est.ebitAvg are fabricated and rejected — the twelfth consecutive file. In every one of the eight years present, ebitdaAvg is exactly 19.962% of revenueAvg and ebitAvg is exactly 16.987%. All forward valuation uses epsAvg, and it verifies against actuals: the FY2025 epsAvg of $3.652 sits within 0.1% of the $3.65 of adjusted EPS the four quarterly releases produced.

Enterprise value — rebuilt, and the defect is the documented NCI omission. enterpriseValueTTM of $80,536M less market capitalisation is exactly $6,487M, which is the filed net debt at 2026-06-30 — total debt $7,857M less cash $1,370M — to the dollar. So the vendor's net-debt component is correct and current. What it omits is the $330M of noncontrolling interests. Rebuilt: $80,866M, and the vendor is 0.41% low. This is the fifth consecutive batch in which the NCI-omission check has fired, and Colgate's is the smallest instance in this batch — but it is present and it is recorded.

On the rebuilt EV of $80,866M against trailing adjusted EBITDA of approximately $4,977M (FY2025 non-GAAP operating profit of $4,347M plus $630M of depreciation and amortisation), EV/EBITDA is 16.3x — against the vendor's evToEBITDATTM of 21.87x, which is computed on the pretax-derived EBITDA figure rejected in Section 6.

5a. What today's price assumes (the inversion)

At $92.54 — 24.2x FY2026 consensus adjusted EPS and 22.7x FY2027 — the price embeds:

• Adjusted EPS of $3.822 in FY2026 and $4.070 in FY2027. (Consensus; 7 and 12 analysts.) The first half delivered $1.96, so FY2026 needs $1.86 in the second half — a modest sequential decline consistent with the September consensus of $0.91. This is a low bar and we expect it met.
• Organic sales growth stays near 2.4% and does not fall further. (Our derivation; the filing supplies the rate.) This is the most fragile assumption in the price. North America is at MINUS 3.0% on volume down 3.9%; Hill's is at +2.1% on volume down 1.2%; EMEA is buying its 3.2% volume with a 1.2% price cut. Only Latin America and Asia Pacific are growing organic sales above 5%, and Latin America's reported growth was 61% currency.
• The market keeps paying 22-24x forward earnings for a 2.4% organic grower. (Our number.) At 20x FY2027E the stock is $81.4; at 26x it is $105.8. The entire dispersion in the fair-value range is this one number, because the earnings estimate has a 7.3% spread and the multiple has a 30% one.
• The Strategic Growth and Productivity Program is not expanded a third time. (Our number.) It has already gone from $200-300M to $350-550M in nine months, runs to December 2028, and its charges are excluded from every adjusted figure the price is struck on.
• Latin American currencies do not reverse. (Our number.) Foreign exchange supplied 8.4 percentage points of Latin America's 13.7% reported growth and 2.4 points of the company's 4.9%. Latin America is 25.6% of net sales and 41.1% of pre-corporate segment operating profit.

5b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+6.5%, from FY2026E $3.822 to FY2027E $4.070) + multiple drift (HELD, at roughly 23x on the then-forward year) + shareholder yield (+3.9% — a 2.27% dividend plus 1.63% of buyback) ≈ +10%.

Our base assumes the multiple holds and does not expand, and the reason is straightforward: 22.7x forward earnings for a business growing organic sales at 2.4% with its home market in decline is already a full price for quality. Colgate has historically traded in the low-to-mid twenties, so this is neither cheap nor stretched relative to its own history — and the historical multiple was set when North American organic sales were positive.

Note the composition: roughly 60% of the expected return is earnings growth and 40% is capital returned, with none from the multiple. That is a robust shape — it does not require the crowd to change its mind — but it produces a modest number, and a modest number at 22.7x is not an argument for buying.

If the multiple compressed to 20x FY2027E the price is $81.4 (MINUS 12.0%). If it expanded to 26x, $105.8 (+14.3%).

5c. Variant perception (where we differ, what would surprise)

• We have essentially NO variant perception and the market appears not to either. Our base of $94 is 4.1% below the street's $98, and the vendor's own consensus label across 45 analysts is "Hold" — 24 hold against 19 buy and 3 sell. That is the rarest configuration in this programme: a large-capitalisation name on which our view, the sell side's rating and the sell side's price target all say roughly the same thing. When we have no edge we say so, and no-edge names default toward Hold.
• Where we differ from the framing rather than the number: we do not think the adjusted figures should carry the whole weight. GAAP operating profit fell 6% and GAAP diluted EPS fell 5.5% in the June quarter. The difference is a restructuring programme now in its fourth quarter with eleven more to run, twice enlarged, which has been preceded by a "2022 Global Productivity Initiative" that ran through FY2024. Colgate has had a restructuring programme in force continuously since 2022. We report the GAAP line alongside the adjusted one and let the reader weight them.
• We think North American volume is the under-discussed number. MINUS 3.9%, in oral care and personal care, with the 10-Q naming the toothpaste category itself. Colgate has defended North American margin brilliantly — up 120 basis points to 21.6% on funding-the-growth savings — and margin defence on falling volume has a natural limit. Watchable number: North America organic sales in the 2026-10-30 release, MINUS 3.0% in the June quarter.
• Positive surprise that would force a re-rate: North America returning to positive organic sales; or Hill's volume turning positive from MINUS 1.2%, which would restore the growth story to the one segment with structural category expansion; or worldwide net selling prices above 3% without volume loss, which would settle the pricing-power question the knowledge base raises.
• Negative surprise that would break the thesis: a third expansion of the restructuring programme; North American organic sales below MINUS 5%; a Latin American currency reversal, which mechanically removes about 2 points of reported growth and hits the segment producing 41% of pre-corporate operating profit; or any further intangible impairment after the Filorga write-down.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $4.070, low $3.960, high $4.250, 12 analysts), cross-checked on EV/EBITDA against the rebuilt enterprise value.

• Bear ~$72 — 18.2x the FY2027 consensus LOW of $3.960. Cross-checks: 18.8x FY2026E; an EV of $63.8bn against FY2027 adjusted EBITDA of roughly $5.3bn, 12.0x; 4.0% below the 52-week low of $74.98. The scenario: North American organic decline widens beyond MINUS 5%, Latin American currencies reverse and remove 2 points of reported growth, Hill's volume keeps falling, the restructuring is expanded again, and a low-growth staple de-rates toward its own historical trough. MINUS 22.2%.
• Base ~$94 — 23.1x the FY2027 consensus MEAN of $4.070. Cross-checks: 24.6x FY2026E; 21.5x FY2028E; an EV of $82.2bn against FY2027 adjusted EBITDA of roughly $5.3bn, 15.5x; a 4.6% free-cash-flow yield on FY2025's $3,634M. Sensitivity, stated openly: 20x gives $81.4 and 26x gives $105.8. The estimate has a 7.3% spread and the multiple assumption has a 30% one, so the multiple is doing all the work. The scenario: organic sales stay near 2.4%, funding-the-growth savings keep adjusted margin expanding at roughly 10 basis points a year, capital return continues near $3bn, and the multiple holds. +1.6%.
• Bull ~$114 — 26.8x the FY2027 consensus HIGH of $4.250. Cross-checks: 26.1x FY2028E; 15.0% above the 52-week high of $99.14; 16.3% above the street's $98 and 4.6% above the street high of $109. The scenario: North America returns to organic growth as the toothpaste category stabilises, Hill's volume turns positive, worldwide pricing exceeds 3%, the restructuring completes on the current budget, and the market pays a premium multiple for defensive earnings in a risk-off regime — which a beta of 0.319 makes a genuine possibility. +23.2%.

Base is 1.6% above spot; asymmetry roughly 1.05:1 (22.2% down, 23.2% up), before a shareholder yield of approximately 3.9%. A base case at the price, a payoff ratio of one, and no variant perception is the textbook definition of Hold, and we are going to use the word rather than reach for a more interesting one.

6. Data integrity — what we rejected and why

Eight findings, including one of the cleanest seg_prod blocks and one of the worst seg_geo blocks in this batch.

1. seg_geo contains SEGMENT NAMES instead of geographies, has only one year, and its values are wrong — REJECTED in full. The entire block is:

> [{"symbol": "CL", "fiscalYear": 2025, ..., "data": {"Oral, Personal and Home Care": 4776000000, "Pet Nutrition": 3062000000}}]

Those are Colgate's two reportable product segments, not geographies. And the values do not correspond to the segments either: seg_prod reports the same two segments for FY2025 at $15,769M and $4,613M, summing to total revenue of $20,382M, whereas these figures sum to $7,838M — 38% of revenue. So the block is simultaneously mislabelled, incomplete (one year), and populated with figures that reconcile to nothing in the filings. This is two of the documented seg_geo failure modes at once — a segment name in place of a geography, and values wrong by a large factor — and it is the ninth consecutive batch in which this field has failed on at least one name. All geographic figures in this dive come from the 10-Q's segment tables.

2. inc_a.operatingIncome is a NON-GAAP figure carrying a GAAP label — REJECTED, and the FY2025 match is exact. The vendor reports FY2025 operating income of $4,348M. The 10-K reports GAAP operating profit of $3,306M, down 23%, and separately reports non-GAAP operating profit of $4,347M. The vendor's figure is the non-GAAP one to within $1M of rounding. The difference is the $919M of goodwill and intangible impairment charges, the ERISA litigation charge and the restructuring charges. Consequence: operatingProfitMarginTTM of 20.65% describes an adjusted margin; the company reported a GAAP operating margin of 16.2% for FY2025 and 19.0% for the June 2026 quarter. The FY2024 figure ($4,383M against a filed GAAP $4,268M and a filed non-GAAP $4,353M) is likewise above GAAP.

3. inc_a.ebitda is derived from pretax income and is therefore depressed by the impairment — REJECTED. FY2025 ebitda reads $3,956M, which is pretax income of $3,059M plus interest of $267M plus D&A of $630M. Adding back the vendor's own operating income of $4,348M and $630M of D&A gives $4,978M. Consequential rejections: ebitdaMarginTTM of 17.50%, evToEBITDATTM of 21.87x and netDebtToEBITDATTM of 1.761x. On the company's non-GAAP operating profit plus depreciation, EV/EBITDA is 16.3x on the rebuilt enterprise value.

4. bal_a puts the entire FY2025 debt balance in longTermDebt and reports shortTermDebt as ZERO — REJECTED. The vendor shows shortTermDebt 0 and longTermDebt $7,988M. The filed balance sheet at 2025-12-31 shows debt payable within one year of $1,117M and long-term debt of $6,871M — the same $7,988M total, allocated entirely differently. The total is right; the maturity profile is not, and currentRatioTTM of 1.026 and quickRatioTTM of 0.671 are computed on current liabilities that do not match the filing. capitalLeaseObligations is also inconsistent: 0 in FY2025 against $563M in FY2024 and $515M in FY2023.

5. Every equity-based ratio is arithmetically correct and analytically void. Total Colgate-Palmolive shareholders' equity is $236M at 2026-06-30 ($54M at 2025-12-31) against $28,931M of treasury stock. Hence priceToBookRatioTTM 312.3x, debtToEquityRatioTTM 33.29x, returnOnEquityTTM 631.1%, bookValuePerShareTTM $0.711 and tangibleBookValuePerShareTTM MINUS $5.058. These are not errors — they are the correct outputs of a formula applied to a balance sheet the formula was not designed for — and every one of them is rejected as a lens for this name. The vendor's own rating block scores CL 1 out of 5 on both debt-to-equity and price-to-book on this basis.

6. enterpriseValueTTM omits noncontrolling interests. The residual over market capitalisation is $6,487M, which is the filed 2026-06-30 net debt to the dollar — an unusually current and accurate net-debt component. It omits the $330M of noncontrolling interests on the same balance sheet. Rebuilt: $80,866M, 0.41% above the vendor's $80,536M.

7. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. Exactly 19.962% and 16.987% of revenueAvg in all eight years. All forward valuation uses epsAvg.

8. Four insider rows are structurally malformed. Four transactions attributed to Betsy Fishbone, all dated 2026-06-01, carry an empty transactionType, an empty acquisitionOrDisposition, and in three cases securitiesTransacted of 0 at a price of 0. A row reporting zero shares at zero price with no transaction type is not a transaction; it is a parsing failure. The fourth reports 9,944 shares at $72.83 with no type and securitiesOwned of 0. These four rows are excluded from the insider analysis in Section 8.

VERIFIED CLEAN — recorded because a clean check is a finding.

capitalExpenditure and netCashProvidedByOperatingActivities are exactly correct in all three years. Capital expenditure $564M / $561M / $705M and operating cash flow $4,198M / $4,107M / $3,745M each match the 10-K to the dollar, making freeCashFlow of $3,634M and the 4.91% yield arithmetically sound. capexToDepreciationTTM of 0.931 is plausible and trips no screen. The 10-K also guides 2026 capital expenditure to "approximately 3.0% of Net sales" — roughly $643M, 14% above FY2025 — which nothing in the payload contains.

seg_prod is exactly correct and complete. FY2025 Oral, Personal and Home Care $15,769M plus Pet Nutrition $4,613M equals $20,382M, which is consolidated net sales to the dollar, and the identity holds across all fifteen years present. A perfect seg_prod block sitting next to a seg_geo block that contains the wrong field entirely is a useful reminder that these two fields fail independently.

Non-equity tripwire — checked and passed. CL is common stock, $1.00 par value, NYSE-listed, per the 10-Q balance sheet (2,000,000,000 shares authorised, 1,465,706,360 issued, 797,172,829 outstanding at 2026-06-30). Price of $92.54 is not par-like; beta is 0.319; volume was 5.07M shares (~$469M of turnover); the 52-week band of $74.98 to $99.14 is a 32% range — the narrowest in this batch, as befits the lowest beta. This is common equity. Note the four series of notes also listed on the NYSE under CL29, CL34, CL35 and CL39; none of them is this security.

7. Knowledge base — four claims about crude oil and one about a basket

Raw hits: 5. Surviving a case-sensitive entity test: 5. Actually about Colgate-Palmolive: 1. Discarded as a futures-contract homograph: 4.

The sweep ran entity terms CL, Colgate and Colgate-Palmolive plus free text on colgate, toothpaste, Hill's pet and pet nutrition across all 52,021 distilled claims.

The purge, and it is the finding. CL is the NYMEX ticker for West Texas Intermediate crude oil futures. Four of the five entity matches are commodity claims:

> 2026-05-23 · BEARISH · conviction 82 · doomberg · speaker Doomberg · entities: oil, CL · categories: oil, commodities — "Oil goes much lower assuming the Middle East isn't re-inflamed — we're drowning in it; Strait of Hormuz is closed yet price is low, proof of oversupply."

> 2026-05-23 · BEARISH · conviction 80 · doomberg · speaker Doomberg · entities: oil, CL · categories: oil, OPEC — "OPEC is dead; Western Hemisphere already outproduces the Middle East, with ~10 million barrels/day of incremental oil to bring online across the Americas."

> 2026-06-30 · neutral · conviction 45 · andreas_steno · speaker Andreas · entities: CL · categories: oil, geopolitical risk — "Everyone's short oil per speculator data; price action stays benign and physical oil flows decently despite the Strait of Hormuz weekend war."

> 2025-11-23 · bullish · conviction 50 · jordi_visser · skill 2.0 · entities: CL · categories: oil, energy — "Oil marched down toward 50 against my call this year, but I believe oil will go higher next year."

Every one carries oil, commodities, OPEC or energy categories. Not one mentions toothpaste, pet food, consumer staples or a brand Colgate owns. A case-sensitive entity test does not rescue a two-letter ticker that is also a widely quoted futures contract, and the only reliable filter is reading the content. These four are discarded in full, and they are recorded here because a naive conviction score on CL would have picked up a bearish 82 and a bearish 80 from a high-skill channel and reported the knowledge base as strongly negative on Colgate-Palmolive. It is not. It has no view. This is the same failure mode the store registry documents for CEG matching Constellation Software, PWR matching Quanta Computer and EMR matching Emerson Collective.

The one claim that is genuinely about Colgate, verbatim:

> 2026-01-28 · BULLISH · conviction 70 · horizon: thesis · skill 0.7 · entities: PG, JNJ, KO, CL, NEE, DUK · channel: ray_dalio · speaker: "uncertain" · role: independent · categories: pricing power, dividend aristocrats

> "Allocate 30-35% to businesses with pricing power that raise prices faster than inflation — dividend aristocrats in staples (PG, KO, CL), utilities (NEE, DUK) and healthcare (JNJ), payout below 60%."

Three qualifications before it is weighted. It is a basket allocation prescription naming CL as one of six examples, not a single-name thesis. Its speaker field reads "uncertain" on a named channel, which under the attribution policy is the weakest form of a named-channel claim. And its skill weight is 0.7, below the default.

But it states two falsifiable screens, and Colgate's own filings answer both.

On pricing power — the claim's first criterion — the filings are equivocal at best. Worldwide net selling prices rose 1.6% in the June quarter. In Europe, Middle East and Africa net selling prices FELL 1.2%. In North America prices rose 0.9% while volume fell 3.9% and the 10-Q named "an organic sales decline in the toothpaste category" in the United States. Only Hill's Pet Nutrition took real price — +3.9% — and it lost 1.2% of volume doing so. A company raising worldwide prices 1.6% while cutting them in one region and losing units in its home market is not an obvious example of "raising prices faster than inflation".

On payout — the claim's second criterion — Colgate fails on trailing GAAP and passes on forward adjusted. dividendPerShareTTM of $2.10 against netIncomePerShareTTM of $2.557 is an 82% payout, well above the claim's 60% threshold; FY2025 dividends paid of $1,823M against net income of $2,132M is 85.5%. On FY2026 consensus adjusted EPS of $3.822 the payout is 55%, below the threshold. So whether Colgate qualifies under this claim's own rule depends entirely on whether you use GAAP or adjusted earnings — which is the same question Section 2 raises about the restructuring programme.

Attribution note. Four of the five hits carry named speakers with independent roles, and all four are about oil. The one Colgate claim carries speaker: "uncertain". No claim in this file carries a management speaker_role. No concentration test is meaningful across a single relevant claim.

Conclusion. Breadth 1, claim count 1, net conviction neutral-empty. The Synthos knowledge base has no view on Colgate-Palmolive. What it has is four opinions about crude oil that share a ticker, and one asset-allocation rule that names Colgate as an example and whose own criteria Colgate half meets. We report that rather than manufacturing a lane.

8. Technicals

• Price $92.54. MINUS 6.7% from the 52-week high of $99.14; +23.4% above the 52-week low of $74.98. Position within the annual range: 72nd percentile.
• Above both moving averages: +1.8% above a 50-day average of $90.91; +7.4% above a 200-day average of $86.17, with the 50-day above the 200-day. A textbook slow uptrend.
• RSI 52.9 — neutral. MACD +0.12, marginally positive.
• Current distance from the six-year peak: MINUS 14.9%, against MINUS 6.7% from the 252-day high. The two differ, so the six-year peak sits outside the last twelve months — this is the field working correctly, not a defect.
• Relative performance is consistently behind and consistently narrow: 3-month +8.4% against SPY +7.6% — a rare, if small, outperformance; 6-month +0.7% against SPY +11.1%; 12-month +10.8% against SPY +24.3% and QQQ +30.8% — a 13-point deficit. The shape is what a low-beta staple does in a rising market: it lags on the way up and the last quarter has been slightly better as defensiveness came back into favour.
• Beta 0.319 — the lowest in this batch by a factor of four against the median. In a genuine market drawdown this is the name in the batch that falls least, and that is a real property of the security, not a narrative.
• Sentiment: 19 buy, 24 hold, 2 sell across 45 analysts, and the vendor's own consensus label is "Hold" — one of only two names in this batch where it is not "Buy". Consensus target $98 (+5.9%), median $100, high $109 (+17.8%), low $79 (MINUS 14.6%). The spread from $79 to $109 is 38% of the low — the tightest coverage dispersion in this batch, which is what forty-five analysts modelling a toothpaste company produce.

Today's move and what it does to the entry

CL closed 2026-08-04 at $92.54, up 2.97% or $2.665 from $89.875. It opened at $89.36, which was near the low of $89.17, traded to $92.74 and closed within 0.2% of the high on 5.07M shares. A 2.97% single-day move in a stock with a beta of 0.319 is unusual and represents roughly nine times its typical beta-implied response to a market move.

No company-specific filing is dated 2026-08-04. The last event was the 2026-07-31 earnings release, four days earlier, which beat the consensus adjusted EPS estimate by 4.5%. The most plausible reading of a 3% move four days after results in a defensive staple is a rotation into defensiveness rather than a company-specific development — but this file cannot establish that, and we do not assert it.

The practical effect on the entry is that we are buying after a 3% up-day into a stock already above both moving averages. That is not a discount.

9. Insiders — three director grants, one tax withholding, and four malformed rows

The reading, and it is close to null. Three of the eight rows are A-Award director grants of 209 to 293 shares on a single date at a single price — the annual retainer, carrying no signal. One is an F-InKind by the chief operating officer for the Americas: 23,347 shares withheld at $90.66 to cover tax on vesting, the mechanically signal-free transaction type, after which he holds 72,481. Four rows are structurally broken — no transaction type, no acquisition/disposition flag, and in three cases zero shares at zero price — and are excluded from the analysis, as noted in Section 6.

What the file contains: not one open-market purchase and not one open-market sale. What it does not contain: any transaction by Noel R. Wallace, the chairman, president and chief executive, or by the chief financial officer.

Two things are nonetheless worth recording. The director grants were priced at $89.45 on 1 July, and the stock closed at $92.54 on 4 August — 3.5% higher in five weeks. And Shane Grant, the chief operating officer for the Americas, is the executive responsible for the region whose organic sales fell 3.0%; his transaction was a tax withholding rather than a sale, which is the correct thing to note about it and also the limit of what can be inferred.

10. Verdict, kill-criteria and flip conditions

Hold.

We are going to use the word rather than reach for a more interesting one, and set out exactly why.

The arithmetic lands on the price. At $92.54 Colgate trades at 24.2x FY2026 consensus adjusted EPS of $3.822 and 22.7x FY2027's $4.070. Our base fair value of $94 is 1.6% above spot with 1.05:1 asymmetry and a 3.9% total shareholder yield. Our number is 4.1% below the street's $98, and the vendor's own consensus label across 45 analysts is "Hold", with 24 holds against 19 buys. This is the rarest configuration in this programme: our view, the sell side's rating and the sell side's target all say roughly the same thing. When we have no edge we say so.

What is genuinely good. A beta of 0.319, the lowest in this batch by a distance, on products people buy monthly regardless of the cycle. Gross margins above 60% and a funding-the-growth savings engine delivering 240 to 320 basis points of gross-margin benefit in every single region this quarter, which lifted adjusted operating margin 10 basis points to 21.4% despite significantly higher raw and packaging material costs. $3,634M of free cash flow on $564M of capital expenditure, with capex and operating cash flow verified exactly correct against the filing in all three years. $3,033M returned to shareholders in FY2025. Latin America organic sales +5.3% and Asia Pacific +5.2%. Net debt of $6,487M at roughly 1.3x adjusted EBITDA with only $34M due within one year.

What holds it at Hold, in four specifics. Organic sales grew 2.4%, and more than half the reported 4.9% was currency. North America organic sales fell 3.0% on volume down 3.9%, with the 10-Q naming "an organic sales decline in the toothpaste category" — in Colgate's core category, in its home market. Hill's Pet Nutrition, the segment that carried the growth story for a decade, grew 2.1% organic on price of +3.9% and volume of MINUS 1.2%. And GAAP operating profit fell 6% while adjusted operating profit rose 5%, the difference being a restructuring programme the board expanded on 2026-04-30 from $200-300M to $350-550M of cumulative pre-tax charges, running to December 2028, and preceded by a "2022 Global Productivity Initiative" that ran through FY2024 — so Colgate has been in continuous restructuring since 2022.

Why not Watch. Because there is no dated event that would resolve anything. Colgate's next print is 87 days away and will most likely show organic sales near 2.4% again. Watch implies a pending resolution; this is a business whose trajectory is well established and fairly priced.

Why not Avoid. Because there is nothing broken here. The margin engine works, the balance sheet is sound, the cash flow is real and verified, and the products do not go away. A 2.4% organic grower at 22.7x forward earnings with a 3.9% shareholder yield is fully priced, not mispriced.

Pre-registered UPGRADE conditions — what would take this to Buy — Tactical:

• North America organic sales returning to positive, from MINUS 3.0%. This is the single condition that would change the growth narrative.
• Hill's Pet Nutrition volume turning positive, from MINUS 1.2% — restoring growth to the only segment with structural category expansion.
• Worldwide net selling prices above 3% without volume loss, which would settle the pricing-power question and, incidentally, validate the one knowledge-base claim on this name.
• A price below roughly $80, which on the base of $94 would restore a payoff ratio above 2:1 without any change to the estimate — and would put the stock near the 200-day average of $86.17.
• Insider buying, or any open-market transaction at all — there is not one in the file.

Pre-registered KILL criteria — what would take this to Watch or Avoid:

• A third expansion of the Strategic Growth and Productivity Program beyond the current $350-550M, or an extension past 2028-12-31.
• North America organic sales below MINUS 5%, or a second consecutive quarter of volume declines worse than 4%.
• A Latin American currency reversal, which mechanically removes roughly 2 points of reported company growth and hits the segment producing 41.1% of pre-corporate operating profit at a 30.4% margin.
• Any further intangible impairment after the $919M Filorga write-down that took skin-health goodwill to $51M.
• Adjusted operating margin falling below 21%, which would mean the funding-the-growth savings have stopped outrunning input costs.
• The buyback falling below roughly $1bn a year, which at 1.63% of market capitalisation is already the smaller half of the shareholder yield.

Where CL fits in the Synthos Framework Portfolio. The defensive sleeve, no position today, with a 2% starter contingent on a price below $80 — a level at which the dividend yield exceeds 2.6% and the forward multiple falls under 20x. Sizing note: with a beta of 0.319, this is the name in this batch that would be added to in a drawdown rather than trimmed, and the correct time to establish it is when the market is not paying up for defensiveness. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $92.54, with the fair-value anchors, kill criteria and upgrade conditions all gradeable.

Single biggest risk: that North America is structurally rather than cyclically shrinking. Organic sales fell 3.0% on volume down 3.9%, and the cause the company names is "an organic sales decline in the toothpaste category" — the category Colgate is. North America is roughly 16.6% of net sales and its operating margin rose 120 basis points to 21.6% on cost savings, which is exactly what a well-run company does when volume falls: it defends profit. That defence has a limit, and the limit is reached when advertising and price can no longer hold share. The offsetting consideration is genuine: Colgate is a global business, and Latin America and Asia Pacific — together 40.2% of net sales — grew organic sales above 5% this quarter. A company can lose units in a mature home market and still compound, and Colgate has done exactly that for a decade. We are simply not willing to pay 22.7x forward earnings for the privilege, and $80 is the number at which we would be.

Provenance & disclosures

• Traceability: 1 knowledge-base claim is genuinely about Colgate-Palmolive out of 52,021 distilled claims (raw hits 5, surviving a case-sensitive entity test 5, actually about the company 1, discarded as futures-contract homographs 4; breadth 1, net conviction neutral-empty). The purge is the finding: CL is the NYMEX ticker for West Texas Intermediate crude oil futures, and four of the five entity matches are commodity claims — doomberg 2026-05-23 (bearish 82, "we're drowning in it"), doomberg 2026-05-23 (bearish 80, "OPEC is dead"), andreas_steno 2026-06-30 (neutral 45, "Everyone's short oil per speculator data") and jordi_visser 2025-11-23 (bullish 50, "I believe oil will go higher next year") — every one carrying oil, commodities, OPEC or energy categories and none mentioning a Colgate product. A naive conviction score would have read a bearish 82 and a bearish 80 from a high-skill channel as a strong negative view on a toothpaste company. It is not; the store has no view. This is the collision class documented for CEG/Constellation Software, PWR/Quanta Computer and EMR/Emerson Collective. The one real claim: ray_dalio, 2026-01-28, bullish, conviction 70, skill 0.7, speaker: "uncertain", entities PG/JNJ/KO/CL/NEE/DUK — "Allocate 30-35% to businesses with pricing power that raise prices faster than inflation — dividend aristocrats in staples (PG, KO, CL), utilities (NEE, DUK) and healthcare (JNJ), payout below 60%." It is a six-name basket rule rather than a single-name thesis, and its two screens are testable against the filings: worldwide net selling prices rose 1.6% with prices FALLING 1.2% in EMEA and a named toothpaste-category decline in the United States; and the trailing payout is 82% of GAAP earnings per share (above the claim's 60% threshold) but 55% of FY2026 consensus adjusted EPS (below it). No claim carries a management speaker_role. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — income statement, balance sheet, segment results and the volume/price/currency decomposition through 2026-06-30, all filing-verified from the 10-Q filed 2026-07-31; annual figures for FY2025, FY2024 and FY2023 from the 10-K filed 2026-02-23, including the Filorga impairment detail, the GAAP-to-non-GAAP reconciliations and the cash-flow statement · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873598 = 2026-08-04T19:59:58Z ($92.54, +2.97%; 50-DMA $90.91; 200-DMA $86.17; RSI 52.9; MACD +0.12; beta 0.319) · knowledge-base claims 2026-08-04. Colgate's fiscal year is the calendar year. All figures come from the Synthos vendor data file for CL or from the SEC filings in the CL archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-23 (fiscal 2025 — the source of the $919M pre-tax / $794M after-tax skin-health impairment, the reduction of Filorga trademark and customer relationships to "an immaterial amount", the $582M goodwill charge taking skin-health goodwill to $51M, the GAAP operating profit of $3,306M against a non-GAAP $4,347M, the cash-flow statement and the 2026 capital-expenditure guidance of approximately 3.0% of net sales); 10-Q filed 2026-05-01 (March 2026 quarter); 10-Q filed 2026-07-31 (June 2026 quarter — the source of the segment tables, the volume/price/currency decomposition, the balance sheet and the Brazilian Kolynos contingency); 8-K filed 2026-05-01, whose Item 2.05 discloses the 2026-04-30 board approval EXPANDING the Strategic Growth and Productivity Program from cumulative pre-tax charges of $200-300M to $350-550M, with the 70-80% severance composition, the 80-90% cash portion, the 2028-12-31 completion date and the regional allocation — absent from every vendor field; 8-K filed 2026-05-13 (annual meeting vote results); 8-K filed 2026-07-31 (second-quarter earnings — note that Exhibit 99, the press release itself, is not present in the extracted text; the quarter's figures in this dive come from the 10-Q filed the same day). All carry preserved [TABLE] statement data where applicable.
• Where the filings contradicted or corrected the vendor (detailed in Section 6): seg_geo, which contains the two PRODUCT SEGMENT names in place of geographies, covers a single year, and reports values summing to $7,838M against $20,382M of FY2025 revenue — mislabelled, incomplete and numerically unreconcilable simultaneously; inc_a.operatingIncome of $4,348M for FY2025 against the filed GAAP $3,306M, matching the filed NON-GAAP figure of $4,347M to within $1M and therefore reporting an adjusted number under a GAAP label, which invalidates operatingProfitMarginTTM of 20.65% against a filed GAAP margin of 16.2%; inc_a.ebitda of $3,956M, derived from pretax income and therefore depressed by the impairment, invalidating ebitdaMarginTTM (17.50%), evToEBITDATTM (21.87x) and netDebtToEBITDATTM (1.761x); bal_a, which reports shortTermDebt of ZERO against the filed $1,117M of debt payable within one year at 2025-12-31 and places the entire $7,988M in longTermDebt against a filed $6,871M, distorting currentRatioTTM and quickRatioTTM, with capitalLeaseObligations inconsistent at 0 in FY2025 against $563M and $515M in the two prior years; enterpriseValueTTM, whose $6,487M residual is the filed 2026-06-30 net debt to the dollar but which omits $330M of noncontrolling interests, leaving it 0.41% low against a rebuilt $80,866M; est.ebitdaAvg/ebitAvg, fabricated at exactly 19.962% and 16.987% of revenue in every one of eight years; four malformed insider rows carrying empty transaction types and zero shares at zero price; and every equity-based ratio — price-to-book 312.3x, debt-to-equity 33.29x, return on equity 631.1%, book value per share $0.711, tangible book value per share MINUS $5.058 — which are arithmetically correct outputs of formulas applied to a balance sheet carrying $28,931M of treasury stock against $236M of shareholders' equity, and are rejected as a class. Above all: the 2026-04-30 expansion of the restructuring programme is absent from every vendor field. Where vendor and filing AGREED — recorded, because a clean check is a finding: capitalExpenditure is exactly correct in all three years ($564M / $561M / $705M), as is netCashProvidedByOperatingActivities ($4,198M / $4,107M / $3,745M), making freeCashFlow of $3,634M and the resulting 4.91% yield sound; and seg_prod is exactly correct and complete, with FY2025 Oral, Personal and Home Care of $15,769M plus Pet Nutrition of $4,613M equalling consolidated net sales of $20,382M to the dollar, and the identity holding across all fifteen years present — a perfect seg_prod sitting beside a seg_geo populated with the wrong field entirely, which is a useful demonstration that the two fail independently.
• Basis note: analyst estimates are on adjusted diluted EPS, which excludes goodwill and intangible impairment charges, Strategic Growth and Productivity Program charges, the ERISA litigation matter and acquisition-related costs. The June 2026 bridge is a single item: $129M of programme charges booked in Corporate, taking GAAP diluted EPS of $0.86 to adjusted $0.99 — a 15% adjustment. The FY2025 bridge was larger: GAAP $2.63 to adjusted $3.65, of which $0.98 was the Filorga impairment. This dive reports the GAAP figures alongside the adjusted ones throughout, because the excluded programme runs to 2028-12-31 and follows a prior programme that ran through 2024. est.ebitdaAvg and est.ebitAvg are rejected outright; all forward valuation uses epsAvg, which verifies against actuals — the FY2025 epsAvg of $3.652 sits within 0.1% of the $3.65 the four quarterly releases produced.
• Estimate coverage: 15 analysts on FY2026 revenue but only 7 on FY2026 EPS, rising to 12 on FY2027 EPS — the anchor for all three fair values, with an FY2027 range of $3.960 to $4.250, a 7.3% spread, the narrowest in this batch — then falling to 5 on FY2028 and 1 on each of FY2029 and FY2030, both of which are excluded from every conclusion.
• Peer note: the vendor peer set — Coca-Cola Europacific Partners, Church & Dwight, Clorox, Diageo, Estée Lauder, Kimberly-Clark, Kroger, Kenvue, Mondelez, Monster Beverage — contains three genuine household-and-personal-care comparables (Church & Dwight, Clorox, Kimberly-Clark) and one adjacent (Kenvue); the remainder are beverages, spirits, snacks and a supermarket. Procter & Gamble, the single most relevant comparable in existence, is absent — and it is one of the six names in the knowledge base's one Colgate claim. Unilever and Reckitt are likewise absent. No peer-multiple comparison is drawn.
• Fair-value caveat: the $72 / $94 / $114 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 18.2x the low of $3.960, 23.1x the mean of $4.070, and 26.8x the high of $4.250 — cross-checked on EV/EBITDA against a rebuilt enterprise value of $80,866M and against free cash flow. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 20x gives $81.4 and 26x gives $105.8. Because the earnings estimate has a 7.3% spread and the multiple assumption has a 30% one, the multiple is doing essentially all the work in the fair-value range, and that is stated rather than concealed. The base assumes the multiple holds at roughly 23x — no expansion, no compression — so the expected return is about 60% earnings growth and 40% capital returned, with none from a re-rating.
• Guidance note: the Strategic Growth and Productivity Program's $350-550M range, its 70-80% severance composition, its 80-90% cash portion, its 2028-12-31 completion date and its regional allocation, together with the 2026 capital-expenditure guidance of "approximately 3.0% of Net sales", are management and board statements, half-weighted under the standing house rule. The audited and reviewed figures — net sales, the volume/price/currency decomposition, segment operating profit, the balance sheet, cash flow and the impairment charges — are not.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.